Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial
Mary Kathryn Dahlgren, Kelly A. Sagar, Ashley M. Lambros, Rosemary T. Smith, Staci A. Gruber
Abstract
This cohort study examines whether consumption of a high-cannabidiol product resulted in detectable amounts of Δ9-tetrahydrocannabinol metabolites in the urine samples of participants.
Topics & Concepts
CannabidiolDronabinolOpen labelMedicineTetrahydrocannabinolUrinary systemClinical trialPharmacologyCannabisInternal medicineCannabinoidPsychiatryReceptorCannabis and Cannabinoid ResearchReligion, Spirituality, and PsychologyBipolar Disorder and Treatment